Search
News 2014
November 2014
November 2014
November 2014
October 2014
September 2014
August 2014
August 2014
July 2014
July 2014
June 2014
News 2014  >  September 2014

September 2014

Enzymotec Ltd Appoints National Manager for Australia and New Zealand. Company to Open Office in Australia to Support Future Growth.

MIGDAL HA'EMEQ, Israel, September xx, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) (the "Company"), today announced the hiring of Mrs. Claudette Cross as its national manager for Australia and New Zealand, a newly created position. In this sales role, Mrs. Cross  will be responsible for the growth and development of Enzymotec's operations and cultivating the Company’s valued partners in Australia and New Zealand.

 

Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd., stated, “We are excited have Claudette join our team to support our future global growth and new office in Australia.  We look to leveraging her extensive sales experience within the nutrition markets to further expand our business in the south pacific market.”

Prior to joining Enzymotec, Mrs. Cross held the position of Sales & Marketing Manager - Health and Personal Care for Bronson & Jacobs, a leading specialty ingredients supplier.  She has over ten years experience in sales and product management in the health, pharmaceutical and nutritional sectors working with Australian and International companies in these fields.  Mrs. Cross attained her M.B.A from the Australian Graduate School of Management and her Bachelor of Chemical Engineering from the University of Sydney.

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
For more information, visit
www.enzymotec.com.

Forward Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: we depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; a high proportion of the sales of our INFAT® product is sold to end users by a single company in China; we are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; we may be required to pay royalties on sales of our krill products in North America and Australia; we have in the past, and may in the future, become subject to litigation regarding intellectual property rights or other matters; our offering of products as ''medical foods'' in the United States may be challenged by regulatory authorities; we rely on our Swedish joint venture partner to manufacture INFAT®, and have recently entered into an arbitration proceeding with our partner with respect to certain matters related to the joint agreement; we are dependent on a single facility that houses the majority of our operations; we may be impacted by delays in manufacturing as we expand our capacity; we may not be able to expand our production or processing capabilities or satisfy growing demand; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we and our customers are subject to significant and increasing government regulations regarding the sale and marketing of our products and our customers' products incorporating our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on February 13, 2014. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. 

 

 

 

 

 

  Home Page | Site Map | Contact Us  
Signed by CDTech - Web Development and Design  
Disclaimer: These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat , cure or prevent disease.
Copyright (©) 2015 Enzymotec Ltd. All rights reserved.